Jennewein Biotechnologie GmbH

Booth 32

Jennewein Biotechnologie GmbH has been founded in May of 2005. Since its foundation, it has developed an innovative method that allows human milk oligosaccharides (HMOs) to be produced on industrial scale. For the production of these products specific fermentation processes were established, upon the basis of in-house research results.

Human Milk Oligosaccharides are a group of rare functional sugar molecules, which constitute the third most abundant group of solid components of human milk besides lipids and Lactose. Due to its specific characteristics they can be used in the food, pharmaceutical and cosmetics industry.

Scientific studies had shown, that human Milk Oligosaccharides have a positive effect on the development of the intestinal flora from babies. The studies had also demonstrated the protective effect of HMOs against bacterial and viral infections as for example diarrhea caused by bacterial pathogens or gastro-intestinal diseases caused by Norovirus. Generally, a positive effect of HMOs on the infant’s immune system as well as on brain development was also reported by several studies during the last decade.

The HMO 2‘-Fucosyllactose, which is produced by fermentation, currently is used as food suplement in infant nutrition in the USA and Europe. In 2015, the US Food and Drug Administration (FDA) granted Jennewein Biotechnologie a license to market 2′-Fucosyllactose in the USA. 2017 2’-Fucosyllactose get the approval for Europe. 2’-Fucosyllactose is the first HMO produced by fermentation which is approved for these both markets.

Managing Director of Jennewein Biotechnologie GmbH is Dr.rer.nat. Stefan Jennewein.

Further information under: www.jennewein-biotech.de